VIDEO: Twice-daily Cequa improves signs, symptoms in poorly controlled dry eye disease
Click Here to Manage Email Alerts
NEW ORLEANS — Twice-daily Cequa improved symptoms of dry eye disease and decreased corneal staining in patients who were still symptomatic or exhibiting signs of disease on current therapy, according to a poster presented at Academy ’23.
In a phase 4 study, Josh Johnston, OD, FAAO, and colleagues evaluated the effects of Cequa (cyclosporine ophthalmic solution 0.09%, Sun Ophthalmics), a formulation with nanomicellar technology for improved delivery, on signs and symptoms of dry eye disease in patients treated with Restasis (cyclosporine ophthalmic solution 0.05%, Allergan) for at least 3 months.
“Ultimately this is a newer cyclosporine with a higher concentration of 0.09% vs. the first FDA-approved version, which was 0.05%, and it’s also a different delivery platform,” Johnston, clinical director at Georgia Eye Partners, told Healio.
Researchers enrolled 125 adults (mean age, 65.5 years; 88% women) with inadequately controlled disease, who received one drop of cyclosporine 0.09% twice daily in each eye for 12 weeks, and assessed corneal fluorescein staining and modified Symptom Assessment in Dry Eye (mSANDE) questionnaire results.
According to Johnston, results showed statistically significant improvement in mSANDE scores and corneal fluorescein staining at 4, 8 and 12 weeks.
Collapse
Johnston J, et al. Effect of OTX-101 0.09% on corneal staining and SANDE scores in patients with dry eye disease uncontrolled on cyclosporine ophthalmic emulsion 0.05%. Presented at: Academy; Oct. 11-14, 2023; New Orleans.
Read more about
Click Here to Manage Email Alerts